Synpromics, Sartorius Stedim Cellca Partner
News Dec 07, 2016
Synpromics is pleased to announce a collaboration with Sartorius Stedim Cellca (Cellca) to evaluate and test its customised synthetic promoters with Sartorius’ proprietary mammalian production cell platform. The goal of the programme is to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.
Cellca has developed the Cellca CHO Expression Platform, an efficient system for the production of biologicals using CHO (Chinese Hamster Ovary) cells consisting of a proprietary cell line, growth medium, expression cassettes and fed-batch process. Cellca has already successfully completed more than 40 customer projects using its system. Synpromics has developed a unique panel of CHO specific synthetic promoters, using its proprietary PromPT™ platform, designed and selected for optimised expression of recombinant proteins.
The use of these synthetic promoters is expected to result in shorter cell line development timelines and significantly enhanced yields of biological products.
Dr David Venables, CEO of Synpromics, commented, “The majority of recombinant proteins, including monoclonal antibodies, are produced using the CHO system. We believe that the combination of Cellca’s CHO bioprocessing platform with Synpromics’ synthetic promoters will provide a much more efficient production system. We’re aiming for significantly higher levels of product being achieved which will increase capacity while reducing production costs.”
Dr. Christoph Zehe, Head of Technology Development of Cellca, added, “We are delighted to be working with Synpromics on this exciting project. We believe it will offer significant benefit to our clients in being able to provide a superior production system for biological products.”
Original story from Synpromics. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Synthetic Material That Detects Enzymatic ActivityNews
Scientists integrate protein and polymer building blocks to create stimulus-responsive systemsREAD MORE
Immatics Enters into a Strategic Partnership with GenmabNews
Immatics and Genmab to combine proprietary technologies to create transformative bispecific therapies against novel, proprietary tumor targets.READ MORE